- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Rebyota was recently approved as the first live microbiome-based therapeutic for the prevention of recurrent Clostridioides difficile infection (CDI) and works by restoring the functionality of a patient’s microbiome after antibiotic treatment, said Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital.
Transcript
Can you explain the mechanism of action for Rebyota and the significance of its FDA approval as the first fecal transplant therapy for the prevention of recurrent CDI?
So, it's certainly very exciting that Rebyota was just approved. This is going to be the first live microbiome-based therapeutic that we have—we generally call these products LPBs [live biotherapeutic products]. This is a rectally administered therapy that's meant to be done in the office or in the hospital setting. And again, it's indicated for the prevention of recurrent CDI.
What we know is that with CDI, the patient took antibiotics, which likely led to this infection, and then multiple rounds of antibiotics to treat. And so you've essentially ablated your gut microbiome. Therapies such as Rebyota are really meant to replace the ecology of your gut microbiome, and restore functionality of your microbiome so that you can be able to overcome this infection.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
